The Bing Center for Waldenström's Macroglobulinemia provides care and new therapies through clinical trials to patients with Waldenström's macroglobulinemia and related Immunoglobulin M (IgM) disorders.
The Bing Center for Waldenström's Macroglobulinemia provides a comprehensive range of services for patients with Waldenström's macroglobulinemia, including:
The Bing Center for Waldenström's Macroglobulinemia encompasses a large, international team of laboratory-based and clinical investigators who are striving to find more effective therapies for Waldenström's macroglobulinemia and, someday, a cure.
Steven P. Treon, MD, PhD, Director, Bing Center for Waldenström’s MacroglobulinemiaIrene Ghobrial, MD, Director, Michele & Stephen Kirsch Laboratory
Claudia Paba-Prada, MD
Stacey Chuma, RNSandra Kanan, ARNPJanet Kunsman, NP
Each patient's care combines the finest treatments currently available for Waldenström's macroglobulinemia with innovative new therapies based on research discovered through the collaboration of the center's laboratories and many other scientists from around the world.
The Bing Center for Waldenström's Macroglobulinemia offers patients access to a wide range of clinical research trials. The main goal of clinical research at the Bing Center for Waldenström's Macroglobulinemia is to swiftly and efficiently take discoveries made in the laboratory to the clinic where they can benefit the health and well-being of the patient.
This include studies aimed at improving the outcomes of patients undergoing biological therapies using agents in trials such as Rituxan and bortezomib that attempt to kill Waldenström's macroglobulinemia tumor cells directly. The center also has clinical research trials evaluating supportive therapies like statins and phosphodiesterase inhibitors to help understand the mechanics of the disease.
Waldenström's Macroglobulinemia: 617-632-3823 or 617-632-5138, or use this online form to make an appointment.
Contact your doctor directly, or for general inquiries, call the Hematologic Malignancies program at 617-632-6140.
Hematologic Malignancies DivisionDana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free:
(866) 408-DFCI (3324)